Benitec Biopharma (BNTC) Expected to Announce Earnings on Wednesday

Key Points

• Benitec Biopharma is set to report Q3 2026 results before the market opens on Wednesday, May 13, with analysts forecasting a $0.27 loss per share and $4.55 million in revenue; a conference call is scheduled for May 14 at 9:30 AM ET.
• The company missed the prior quarter (reported a $0.26 loss vs. a $0.23 estimate) and analysts now project steep losses of about $-1 EPS for both the current and next fiscal years.
• Wall Street views are mixed—five Buys, one Hold and one Sell—but the consensus rating is “Moderate Buy” with a consensus target price of $27.67.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) is anticipated to issue its Q3 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.27) per share and revenue of $4.55 million for the quarter. Parties may review the information on the company's upcoming Q3 2026 earning report for the latest details on the call scheduled for Thursday, May 14, 2026 at 9:30 AM ET.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last issued its quarterly earnings results on Thursday, February 12th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.03). On average, analysts expect Benitec Biopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Benitec Biopharma Price Performance

NASDAQ:BNTC opened at $12.20 on Wednesday. Benitec Biopharma has a one year low of $9.85 and a one year high of $17.15. The business has a fifty day moving average price of $11.67 and a 200-day moving average price of $12.50. The firm has a market capitalization of $419.07 million, a price-to-earnings ratio of -10.70 and a beta of 0.28.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Weiss Ratings restated a "sell (d-)" rating on shares of Benitec Biopharma in a research report on Monday, April 20th. Wall Street Zen cut Benitec Biopharma from a "hold" rating to a "sell" rating in a research report on Saturday, February 14th. TD Cowen reissued a "buy" rating on shares of Benitec Biopharma in a report on Monday, March 9th. Finally, HC Wainwright restated a "buy" rating and set a $32.00 target price on shares of Benitec Biopharma in a research note on Monday, March 9th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $27.67.

Institutional Investors Weigh In On Benitec Biopharma

Several large investors have recently made changes to their positions in the company. Barclays PLC increased its stake in Benitec Biopharma by 9.1% in the 4th quarter. Barclays PLC now owns 23,211 shares of the biotechnology company's stock worth $313,000 after acquiring an additional 1,928 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of Benitec Biopharma by 11,114.0% in the second quarter. Rhumbline Advisers now owns 20,858 shares of the biotechnology company's stock valued at $244,000 after purchasing an additional 20,672 shares in the last quarter. Wells Fargo & Company MN increased its holdings in shares of Benitec Biopharma by 78.1% in the 4th quarter. Wells Fargo & Company MN now owns 16,262 shares of the biotechnology company's stock worth $219,000 after buying an additional 7,129 shares during the last quarter. Squarepoint Ops LLC bought a new stake in Benitec Biopharma during the fourth quarter worth approximately $203,000. Finally, Jane Street Group LLC purchased a new stake in Benitec Biopharma during the fourth quarter valued at approximately $167,000. 52.19% of the stock is owned by institutional investors.

About Benitec Biopharma

Benitec Biopharma Ltd NASDAQ: BNTC is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company's proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.

Benitec's lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.